The Mind-CM study, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, aims to evaluate the efficacy and cost-effectiveness of integrating mindfulness-based therapy with standard pharmacological prophylaxis in chronic migraine patients. Given the prevalence of chronic migraine and the significant burden of medication overuse, successful outcomes could position mindfulness therapy as a viable adjunct treatment, potentially leading to reduced healthcare costs and improved patient quality of life. The market for migraine treatments is substantial, with ongoing demand for innovative, effective solutions. If the study demonstrates significant benefits, it may attract interest from pharmaceutical companies looking to expand their product offerings in the migraine space, as well as healthcare providers seeking cost-effective treatment options.